Diagnosis and Initial Treatment of CLL
Peter Hillmen et al.
Re-evaluating the role of epigenetics in multiple myeloma
Brian Walker et al.
Overview of a Phase Ib study of venetoclax and obinutuzumab in CLL
What impact have new minimal residual disease (MRD) assessment techniques had in myeloma?
Panel discussion on novel therapies and targets for lymphoma
John Gribben et al.